Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
Abstract: Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hs?90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia.
Type:
Application
Filed:
March 30, 2007
Publication date:
October 27, 2011
Applicants:
DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Haley Vinson-Hieronymus, Todd R. Golub, Justin Lamb, Kimberly Stegmaier
Abstract: Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein.
Type:
Application
Filed:
June 10, 2011
Publication date:
October 27, 2011
Applicant:
Arizona Board of Regents on behalf of the University of Arizona
Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.
Type:
Application
Filed:
November 6, 2009
Publication date:
October 27, 2011
Applicant:
WARF - Wisconsin Alumni Research Foundation
Inventors:
Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
Abstract: The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.
Type:
Application
Filed:
April 6, 2009
Publication date:
October 27, 2011
Applicants:
MUSEUM NATIONAL D'HISTOIRE NATURELLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Jean-Pierre Kolb, Faouzia Menasria, Christian Billard, Michèle Meyer, Anatole Guy Azebaze, Augustin Ephrem Nkengfack
Abstract: The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative.
Type:
Grant
Filed:
August 30, 2007
Date of Patent:
October 18, 2011
Assignee:
The Governors of the University of Alberta
Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.
Type:
Grant
Filed:
November 10, 2006
Date of Patent:
October 18, 2011
Assignee:
Johnson Matthey Public Limited Company
Inventors:
Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
Abstract: This invention relates to a group of compounds for repelling blood-feeding ectoparasitic arthropods, and a method of deterring their landing and feeding on animals including humans, by applying in one or more formulations compounds that incorporate one or more sulfide and one or more hydroxyl groups to the skin, clothing or environment of animals, including humans. A method of repelling and deterring landing and feeding by blood-feeding arthropods on an animal by applying in effective amount one or more compounds that incorporate alkyl sulfide and alcohol moieties, or alkyl sulfide and amide moieties, or alkyl sulfide and amide moieties to the skin, clothing or environment of an animal.
Type:
Application
Filed:
September 25, 2009
Publication date:
October 13, 2011
Inventors:
Regine M Gries, Grigori Khaskin, Gerhard G. Gries
Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.
Type:
Application
Filed:
March 8, 2011
Publication date:
October 6, 2011
Applicant:
BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
Type:
Application
Filed:
December 22, 2010
Publication date:
September 29, 2011
Applicant:
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Inventors:
Matthew E. BUROW, Stephen M. BOUE, Thomas T.Y. WANG, Deepak BHATNAGAR, Charles E. WOOD, Mark A. HEIMAN
Abstract: This invention belongs to the chemical-pharmaceutical field. New compounds of pterocarpanquinone family presented in formula (I) according to this invention are capable to be activated by reduction generating alkylating species intracellularly. It presents selective cytotoxic effects particularly on mammalian human and nonhuman cells that divide constantly and are useful in treating diseases and dysfunctions related to the phenomenon of undesired cell proliferation. Such compounds are also effective for the treatment of diseases or dysfunctions related to high levels of TNF-? in human and nonhuman mammals.
Type:
Application
Filed:
November 5, 2009
Publication date:
September 15, 2011
Applicant:
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
Inventors:
Alcides Jose Monteiro Da Silva, Vivian Mary Barral Dold Rumjanek, Bartira Rossi Bergmann, Eduardo Salustiano Jesus Dos Santos, Paulo Roberto Ribeiro Costa, Chaquip Daher Netto, Wallace Pacienza Lima, Eduardo Caio Torres Dos Santos, Moises Clemente Marinho Cavalcante, Sergio Henrique Seabra, Ingred Goretti Rica
Abstract: Disclosed is the use of pyranopyranone derivatives of formula wherein R1, R2, R3, R4 and R5 independently of one another are hydrogen; C1-C30alkyl, C2-C30alkenyl, or C3-C12cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C6-C20aryl, which may be substituted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G, C2-C18alkenyl, C2-C18alkynyl, C7-C25aralkyl, or —CO—R6; —SiR8R9R10; or R4 and R5 together form a five or six membered ring; or R3 and R4 together form a five or six membered ring; D is —CO—; —COO—; —S—; —SO—; —SO2—; —O—; —NR7—; —SiR8R9—; —POR10—; —CR12?CR13—; or —C?C—; and E is —OR6; —SR6; —NR14R15; —NR14COR15; —COR6; —COOR6; —CONR14R15; —CN; halogen; or OSO3R11; SO3R11; SO2R11; PO3(R11)2; OPO3(R11)2; G is E; C1-C18alkyl, which is optionally interrupted by D; C1-C18 perfluoroalkyl; C1-C18alkoxy, which is optionally substituted by E and/or interrupted by D; wherein R6 is H; C6-C18aryl which is optionally substituted by OH, C1-C30alky
Type:
Application
Filed:
February 16, 2011
Publication date:
September 15, 2011
Applicant:
BASF SE
Inventors:
Barbara Wagner, Janina Purschwitz, Karin Bieler
Abstract: A method for inhibiting the production of cytokines of T helper cell type II (Th2 cell) and/or inhibiting the production of chemokines in a mammal is provided, wherein the method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound of formula (I), pharmaceutically acceptable salts and esters of the compound, and combinations thereof:
Abstract: This invention relates to treatment of neuro-psychiatricdisorders. Specifically, the invention relates to the use of small molecule agent specific against erbB4, erbB3 or their combination, or fragments thereof in inhibiting the attachment of erbB4, erbB3 or their combination to NRG1.
Abstract: High purity phthalein derivatives are useful for medical applications and/or in the field of biotechnology. The phthalein derivatives are prepared by a method whereby a phthalic anhydride derivative is condensed with a naphthol or phenol derivative in an organic acid ester and the crystals of the resulting condensate are converted by action of a strong acid or one of its precursors in anhydrous medium.
Abstract: The present invention provides zebrafish based methods for the identification of compounds potentially useful in the treatment of motor neuron degenerative diseases (MNDDs), compounds identified by these methods and compositions, methods and medicaments for treating MNDDs.
Abstract: The subject invention relates in part to the oral administration of ecdysteroids for controlling subterranean termites. Preferred ecdysteroids for use according to the subject invention are ecdysone, certain ecdysone analogs, and 20-hydroxyecdysone, for example. In some preferred embodiments, one or more of these compounds is used in a termite bait in combination with one or more chitin synthesis inhibitors. Thus, the subject invention also relates in part to controlling termites by the use of a chitin synthesis inhibitor (CSI), such as hexaflumuron and/or noviflumuron, together with an ecdysteroid (and analogs thereof) or molt-accelerating compound (MAC), such as halofenozide. The subject invention also relates to mixtures comprising these two active ingredients. The MAC/ecdysteroid analog induces a preliminary molting event in termite workers (they could not complete the molting), which then allows the CSI to further disrupt the molt and cause mortality.
Type:
Application
Filed:
April 8, 2011
Publication date:
August 4, 2011
Inventors:
Nan-Yao SU, James Edward King, Paul Allen Neese
Abstract: The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation in the liver of the animal.
Abstract: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
Abstract: The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
Type:
Grant
Filed:
March 6, 2008
Date of Patent:
July 19, 2011
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Nareshkumar F. Jain, Zhihua Sui, Ningyi Chen
Abstract: Novel derivatives of enfumafungin are disclosed herein, along with their, pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
Type:
Application
Filed:
September 25, 2008
Publication date:
July 14, 2011
Applicants:
Merck Sharp & Dohme Corp., Scynexis, Inc.
Inventors:
James M. Balkovec, Phieng Siliphaivanh, Frances A. Bouffard, Roland A. Bouffard, Michael R. Peel, Weiming Fan, Ahmed Mamai, Sarah Dimick Gray
Abstract: The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention.
Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.
Type:
Application
Filed:
February 4, 2011
Publication date:
July 7, 2011
Inventors:
Ze'ev A. Ronai, Anindita Bhoumik, Nicholas D. P. Cosford, Russell Dahl
Abstract: The invention is related to the area of new 6-Oxa-8?-steroid estrogen analogues and the synthesis of these new biological active steroid estrogen analogues, namely, to the preparation of 6-oxa-8?-steroid estrogens and their use as estrogen receptor modulators. These new estrogen analogues are ligands for estrogen receptors and as such may be useful for the treatment and prevention of a variety of conditions related to estrogen functioning. These conditions include bone and cartilage disorders, increased levels of LDL cholesterol, cardiovascular diseases, impairment of cognitive function, cerebral degeneration disorders, endometriosis and other types of inflammation, the metabolic syndrome, and cancer, in particular of the breast, uterus and prostate.
Type:
Application
Filed:
November 10, 2008
Publication date:
June 30, 2011
Applicant:
TOPASS GMBH
Inventors:
Ulrich Pison, Alexander Grigorievich Shawa, Svetlana Nikolaevna Morozkina
Abstract: Compositions and methods for maintenance of cartilage health or prevention, alleviation and/or treatment of cartilage disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting cartilage growth or for the maintenance of cartilage health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical, in particular polyphenol having the ability to treat or prevent muscular skeletal diseases.
Type:
Application
Filed:
February 25, 2008
Publication date:
June 30, 2011
Applicant:
NESTEC S.A.
Inventors:
Elizabeth Offord Cavin, Gary Williamson, Didier Courtois, Bernard Lemaure, Andre Touche, Grace Ing Soon, Laurent Ameye
Abstract: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or hetero-cycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds.
Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.
Type:
Application
Filed:
March 3, 2009
Publication date:
June 16, 2011
Inventors:
Paul W. Erhardt, Rahul Khupse, Jeffrerey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McClachlan
Abstract: Method for modulating or controlling sodium channel current of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.
Type:
Application
Filed:
February 16, 2011
Publication date:
June 16, 2011
Applicants:
U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
Type:
Application
Filed:
December 3, 2010
Publication date:
June 9, 2011
Applicant:
Aquinox Pharmaceuticals Inc.
Inventors:
Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan
Abstract: Certain embodiments of the methods and compositions of matter disclosed herein relate to: “simultaneous” control of rodents and at least one insect pest (e.g., cockroach, ant, tick) using the same bait; control of ticks by orally administering to mammals a diet composition comprising fipronil; enhancing insecticide efficacy through use of a diet composition that comprises a Generation-I rodenticide and an insecticide; use of imidacloprid in a diet composition orally administerable to mammals in an uncontrolled setting; and use of at least one insecticide to enhance the efficacy of a rodenticide.
Abstract: Disclosed is a composition for modulating the release of a neurotransmitter, which includes naturally extracted polyphenols as an active ingredient. The disclosed composition suppresses the formation of a SNARE complex, thereby modulating the release of a neurotransmitter, and thus can be used as a modulator for a reaction within a cell related to the SNARE complex. Such an inhibitor of the SNARE complex formation can be used as a composition for reducing wrinkles and relieving pain.
Type:
Application
Filed:
March 12, 2008
Publication date:
May 12, 2011
Applicant:
SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
Inventors:
Dae-Hyuk Kweon, Yeon-Kyun Shin, Chang-Hwa Jung, Yoo-Soo Yang
Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.
Type:
Application
Filed:
July 15, 2008
Publication date:
May 12, 2011
Applicant:
SCHERING CORPORATION
Inventors:
Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien
Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
Type:
Application
Filed:
November 8, 2010
Publication date:
May 12, 2011
Applicants:
PROLX PHARMACEUTICALS CORP., Arizona Board of Regents on behalf of the University of Arizona, University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Garth POWIS, Peter WIPF, Lynn KIRKPATRICK
Abstract: Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the level of expression of mRNA for a prostate-specific antigen or the level of production of the prostate-specific antigen in the prostate cancer cell; and contacting the substance with an adipocyte and measuring the level of expression of mRNA for uncoupling protein-1 or the level of production of uncoupling protein-1 in the adipocyte. Also disclosed is a selective androgen receptor modulator comprising a compound represented by any one formula selected from the structural formulae (I) to (III) as an active ingredient. Further disclosed is a composition for preventing or treating lifestyle-related diseases, which comprises the selective androgen receptor modulator.
Abstract: Provided herein are methods of treating or preventing pain and/or inflammation in a subject comprising administering to the subject a transient receptor potential (TRP) ion channel inhibitor.
Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
Type:
Application
Filed:
December 12, 2008
Publication date:
April 28, 2011
Applicants:
CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND, Research Foundation of the City University of New York
Inventors:
Julie D. Saba, Henrik Fyrst, Robert Bittman
Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
Type:
Application
Filed:
October 16, 2009
Publication date:
April 21, 2011
Inventors:
KAN HE, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques Dikansky
Abstract: The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells.
Type:
Application
Filed:
March 11, 2009
Publication date:
April 14, 2011
Applicants:
Presidents and Fellows of Harvard College, The General Hospital Corporation
Abstract: Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from germination, which can be exploited in various methods of therapeutic treatment. Also provided is a method of modulating germination of a spore of a Gram-positive bacterium. Also provided is a method of decontaminating an environment.
Type:
Application
Filed:
March 26, 2010
Publication date:
April 14, 2011
Applicant:
The Trustees of Columbia University in the City of New York
Abstract: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.
Type:
Grant
Filed:
June 20, 2008
Date of Patent:
April 5, 2011
Assignee:
The Regents of the University of California
Abstract: Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO2H) has been replaced by an amine group (CH2NR1R2). In some embodiments, the compounds selectively bind to TrkA but not TrkB or C, robustly induce its tyrosine phosphorylation and downstream signaling activation including Akt and MAP kinases. Further, they can strongly prevent glutamate-induced neuronal cell death and provoke prominent neurite outgrowth in PC12 cells. Gambogic amines specifically interact with the cytoplasmic juxtamembrane domain of TrkA receptor and trigger its dimerization. Administration of these compounds in can substantially diminishes Kainic acid-triggered neuronal cell death and decrease infarct volume in transient middle cerebral artery occlusion (MCAO) model of stroke.
Abstract: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.
Abstract: Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.
Type:
Application
Filed:
July 23, 2010
Publication date:
March 17, 2011
Applicant:
Amazentis SA
Inventors:
Christopher L. Rinsch, Philippe V. L. Dupraz
Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by ?-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.
Type:
Application
Filed:
September 21, 2010
Publication date:
March 17, 2011
Inventors:
Gerardo M Castillo, Paula Choi, Alan D Snow
Abstract: The present invention provides preparation methods of protein nanoparticles for in vivo delivery of pharmacologically active agents, wherein said methods are to encase pharmaceutically active agents into proteins or peptides to form nanoparticles by unfolding the protein, and subsequently refolding or assembling the protein to produce a pharmacologically active agent encased within a protein nanoparticle.
Type:
Application
Filed:
August 6, 2010
Publication date:
March 10, 2011
Applicant:
NanoPax Pharma, LLC
Inventors:
Yiqiao Hu, Jinhui Wu, Dawei Ding, Guangming Gong, Xiaolei Tang, Chunhui Tong, Yan Zhu, Shaoling Li
Abstract: A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Syndrome X in a subject through the administration of the cinnamon extract. The cinnamon extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months.
Abstract: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.
Type:
Grant
Filed:
December 24, 2009
Date of Patent:
March 1, 2011
Assignee:
The Regents of the University of California
Abstract: The present disclosure is in relation to antiviral preparations obtained from plant sources namely Cinnamon, Litchi and Arachis. It provides a composition and a process to prepare the composition comprising pentameric procyanidin flavonoid, trimers and tetramers. The composition improves immunity response and found to be useful in treatment and management of HIV infection and AIDS and for the prevention, treatment and management of Influenza virus and infection.
Abstract: The invention provides a device and a compound for the prevention and/or treatment of uterine fibroids in human patients, wherein the compound is dispensed from the device and is administered locally to the uterine tissue.